AUDICOR Heart Failure Management System Granted U.S. Food and Drug Administration Breakthrough Device Designation

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

February 23, 2021

AUDICOR heart failure management system uses clinically tested algorithms to detect the risk of decompensation at home in patients who have been previously hospitalized for heart failure reports Inovise Medical.

Michael Mirro, MD, Director of the Parkview Mirro Center for Research and Innovation, and Clinical Professor of Medicine at Indiana University, commented, “This technology promises to enhance the management of heart failure patients and keep them out of the hospital. Early detection of potential problems outside of the hospital can allow clinicians to modify the patients’ therapeutic regimens and maintain their stable condition.”

The AUDICOR heart failure management system is non-invasive and assesses the mechanical efficiency, as well as the electrical activity, of the heart. Signals are acquired through a hand-held device that connects to a smartphone for analysis in the cloud. This analysis of the signals produces proprietary cardiac acoustic biomarkers, which have been shown to provide actionable data to optimize therapy and improve patient outcomes.

Physicians receive notifications based on biomarker trends and values, allowing them to modify patient therapy (e.g., change drug dosage) before there is a significant deterioration of heart failure status requiring hospitalization.

“The most significant advantages of this new technology are enhanced ease of use, eliminated risks of surgical complications, and significantly reduced costs compared to permanently implanted physiologic sensors currently on the market,” said Peter Bauer, Ph.D., CEO of Inovise Medical

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles